AbbVie vs. Vertex Pharmaceuticals: Comparing Healthcare Investment Value
VRTX Vertex Pharmaceuticals Inc
$514.65 +2.53%
View chart & analysis → - 1AbbVie recorded $61.2 billion in revenue for fiscal year 2025, achieving an 8.6% revenue growth rate for fiscal year 2025.
- 2Vertex Pharmaceuticals revenue for fiscal year 2025 slightly exceeded $12 billion, with a net profit margin of approximately 33% for fiscal year 2025.
- 3AbbVie appears to be a better long-term buying opportunity currently due to lower P/S and P/E ratios and a larger blockbuster pipeline.
So what's the key point?
AbbVie recorded $61.2 billion in revenue, while Vertex Pharmaceuticals had a profit margin of approximately 33%. AbbVie appears to be a better buying opportunity because its stock price is low relative to its earnings and it has a large pipeline of new drug candidates.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.